{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:15:42Z","timestamp":1770488142896,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.vaccine.2016.11.053","type":"journal-article","created":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T01:46:59Z","timestamp":1481248019000},"page":"452-458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants"],"prefix":"10.1016","volume":"35","author":[{"given":"Timo","family":"Vesikari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Da Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Eymin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Boisnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2016.11.053_b0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14760584.8.3.265","article-title":"Prevention of meningococcal serogroup C disease by NeisVac-C","volume":"8","author":"Borrow","year":"2009","journal-title":"Exp Rev Vaccines"},{"issue":"41","key":"10.1016\/j.vaccine.2016.11.053_b0010","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1016\/j.vaccine.2013.07.083","article-title":"Effectiveness of meningococcal serogroup C vaccine programmes","volume":"31","author":"Borrow","year":"2013","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2016.11.053_b0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4161\/hv.27597","article-title":"Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy","volume":"10","author":"Pascucci","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2016.11.053_b0020","unstructured":"European Centre for Disease Prevention and Control [internet]. Vaccine schedule. Available from: <http:\/\/vaccine-schedule.ecdc.europa.eu\/Pages\/Scheduler.aspx> [accessed 27 January 2016]."},{"issue":"6","key":"10.1016\/j.vaccine.2016.11.053_b0025","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/01.inf.0000222413.47344.23","article-title":"The use of combination vaccines has improved timeliness of vaccination in children","volume":"25","author":"Kalies","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.11.053_b0030","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/INF.0b013e31805d7f17","article-title":"Use of combination vaccines is associated with improved coverage rates","volume":"26","author":"Marshall","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.vaccine.2016.11.053_b0035","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1080\/21645515.2015.1044180","article-title":"The value of childhood combination vaccines: from beliefs to evidence","volume":"11","author":"Maman","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2016.11.053_b0040","unstructured":"European Medicines Agency [internet]. Hexyon\u00ae Summary of Product Characteristics. Available from: <http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002796\/human_med_001641.jsp&mid=WC0b01ac058001d124> [accessed 20 May 2016]."},{"key":"10.1016\/j.vaccine.2016.11.053_b0045","unstructured":"Electronic Medicines Compendium (eMC) [internet]. NeisVac-C\u00ae Summary of Product Characteristics. Available from: <https:\/\/www.medicines.org.uk\/emc\/medicine\/30325> [accessed 20 May 2016]."},{"key":"10.1016\/j.vaccine.2016.11.053_b0050","unstructured":"European Medicines Agency [internet]. Prevenar 13\u00ae Summary of Product Characteristics. Available from: <http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001104\/human_med_001220.jsp&mid=WC0b01ac058001d124> [accessed 20 May 2016]."},{"key":"10.1016\/j.vaccine.2016.11.053_b0055","unstructured":"European Medicines Agency [internet]. RotaTeq\u00ae Summary of Product Characteristics. Available from: <http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000669\/human_med_001045.jsp&mid=WC0b01ac058001d124> [accessed 20 May 2016]."},{"key":"10.1016\/j.vaccine.2016.11.053_b0060","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2016.11.053_b0065","series-title":"Modelling binary data","author":"Collett","year":"2003"},{"issue":"12","key":"10.1016\/j.vaccine.2016.11.053_b0070","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk","volume":"9","author":"Farrington","year":"1990","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2016.11.053_b0075","unstructured":"Ceyhan M, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent fully liquid DTaP-IPV-Hep B-PRP-T vaccine given at 2, 3, 4 months of age with a booster at 15\u201318 months compared to licensed vaccines in Turkish infants. [abstract and Poster]. In: 5th Asian Congress of Pediatric Infectious Diseases (ACPID), 23\u201326 September 2010, Taipei, Taiwan."},{"issue":"2","key":"10.1016\/j.vaccine.2016.11.053_b0080","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1128\/CVI.00420-08","article-title":"Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom","volume":"16","author":"Southern","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2016.11.053_b0085","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40272-013-0007-7","article-title":"DTaP-IPV-Hep B-Hib vaccine (Hexaxim\u00ae): a review of its use in primary and booster vaccination","volume":"15","author":"McCormack","year":"2013","journal-title":"Paediatr Drugs"},{"issue":"8","key":"10.1016\/j.vaccine.2016.11.053_b0090","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/01.inf.0000227725.61495.c4","volume":"25","author":"Tejedor","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2016.11.053_b0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/adc.2005.076109","article-title":"Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age","volume":"92","author":"Kitchin","year":"2007","journal-title":"Arch Dis Child"},{"issue":"11","key":"10.1016\/j.vaccine.2016.11.053_b0100","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1586\/erv.11.142","article-title":"Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules","volume":"10","author":"Borrow","year":"2011","journal-title":"Exp Rev Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2016.11.053_b0105","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/INF.0b013e31824b972b","article-title":"13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety","volume":"31","author":"Martin\u00f3n-Torres","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"35","key":"10.1016\/j.vaccine.2016.11.053_b0110","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1016\/j.vaccine.2013.04.070","article-title":"Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C\u00ae) in infants","volume":"31","author":"Poellabauer","year":"2013","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1631115X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1631115X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T23:54:54Z","timestamp":1536191694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1631115X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0264410X1631115X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.053","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2016 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}